Fisher Asset Management LLC grew its holdings in Revvity, Inc. (NYSE:RVTY - Free Report) by 41.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 57,248 shares of the company's stock after purchasing an additional 16,633 shares during the period. Fisher Asset Management LLC's holdings in Revvity were worth $6,389,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Gladius Capital Management LP purchased a new stake in Revvity in the 3rd quarter worth approximately $32,000. Continuum Advisory LLC lifted its stake in shares of Revvity by 2,972.7% in the 3rd quarter. Continuum Advisory LLC now owns 338 shares of the company's stock valued at $43,000 after purchasing an additional 327 shares during the period. MassMutual Private Wealth & Trust FSB lifted its position in Revvity by 55.9% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 385 shares of the company's stock valued at $43,000 after buying an additional 138 shares during the period. Avior Wealth Management LLC lifted its position in Revvity by 7,980.0% during the third quarter. Avior Wealth Management LLC now owns 404 shares of the company's stock valued at $52,000 after buying an additional 399 shares during the period. Finally, Principal Securities Inc. lifted its holdings in shares of Revvity by 54.9% during the fourth quarter. Principal Securities Inc. now owns 598 shares of the company's stock valued at $67,000 after purchasing an additional 212 shares during the last quarter. 86.65% of the stock is currently owned by institutional investors.
In other Revvity news, insider Joel S. Goldberg sold 15,170 shares of the stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $126.73, for a total transaction of $1,922,494.10. Following the transaction, the insider now owns 33,400 shares of the company's stock, valued at $4,232,782. This represents a 31.23 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Tajinder S. Vohra sold 5,492 shares of the stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $116.81, for a total value of $641,520.52. Following the transaction, the insider now owns 19,652 shares in the company, valued at $2,295,550.12. This trade represents a 21.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.60% of the stock is owned by company insiders.
RVTY has been the subject of a number of research analyst reports. Bank of America raised shares of Revvity from a "neutral" rating to a "buy" rating and set a $138.00 target price for the company in a research report on Friday, December 13th. TD Cowen lifted their price target on Revvity from $141.00 to $144.00 and gave the stock a "buy" rating in a research report on Tuesday, November 5th. Barclays boosted their price objective on Revvity from $135.00 to $140.00 and gave the company an "overweight" rating in a report on Monday, February 3rd. KeyCorp upped their price target on shares of Revvity from $132.00 to $145.00 and gave the stock an "overweight" rating in a research report on Monday, February 3rd. Finally, Raymond James reissued an "outperform" rating and set a $145.00 target price (up previously from $140.00) on shares of Revvity in a research report on Monday, February 3rd. Four investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Revvity currently has a consensus rating of "Moderate Buy" and a consensus price target of $136.25.
Get Our Latest Stock Analysis on Revvity
Revvity stock traded up $2.55 during mid-day trading on Wednesday, hitting $111.81. The company's stock had a trading volume of 1,173,052 shares, compared to its average volume of 924,925. The firm has a market capitalization of $13.43 billion, a PE ratio of 50.59, a price-to-earnings-growth ratio of 3.82 and a beta of 1.03. Revvity, Inc. has a 1 year low of $97.32 and a 1 year high of $129.50. The company has a current ratio of 3.60, a quick ratio of 3.03 and a debt-to-equity ratio of 0.41. The stock's fifty day moving average is $116.78 and its two-hundred day moving average is $118.33.
Revvity (NYSE:RVTY - Get Free Report) last released its earnings results on Friday, January 31st. The company reported $1.42 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.37 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. During the same period last year, the firm earned $1.25 earnings per share. On average, analysts anticipate that Revvity, Inc. will post 4.94 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 9th. Investors of record on Friday, April 18th will be issued a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a yield of 0.25%. The ex-dividend date of this dividend is Thursday, April 17th. Revvity's dividend payout ratio is currently 12.67%.
Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
Before you consider Revvity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Revvity wasn't on the list.
While Revvity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.